Valuation : Integrity Applications, Inc.

Market Cap 1.31M 1.13M 1.06M 967K 1.81M 125M 1.82M 12.58M 4.86M 63.52M 4.92M 4.81M 201M P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -2.63M -2.26M -2.13M -1.94M -3.63M -250M -3.64M -25.22M -9.75M -127M -9.86M -9.65M -403M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
89.82%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 55 14/07/2026
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 64 13/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 1.31M
+0.89%-6.98%-2.73%+11.12% 46.38B
+0.17%-0.74%+407.28%+546.58% 44.51B
-0.86%-2.60%+35.51%+20.35% 42.3B
-0.14%-2.98%-0.04%+82.21% 39.91B
0.00%-1.72%+13.42%+42.33% 32.79B
-3.44%-2.43% - - 17.13B
-0.78%-1.13%+20.74%+116.26% 16.36B
+0.20%-3.76%+12.33%+30.49% 14.31B
-0.86%-4.60%+76.86%+39.36% 13.29B
Average +1.03%-2.88%+70.42%+111.09% 29.66B
Weighted average by Cap. -0.32%-3.04%+85.97%+133.03%

Financials

2024 2025
Net sales - -
Net income -22.6M -19.44M -18.31M -16.68M -31.21M -2.15B -31.34M -217M -83.87M -1.1B -84.85M -83.01M -3.47B -19.39M -16.68M -15.71M -14.31M -26.78M -1.84B -26.89M -186M -71.96M -940M -72.8M -71.22M -2.98B
Net Debt -5.35M -4.6M -4.33M -3.95M -7.39M -509M -7.42M -51.37M -19.86M -259M -20.09M -19.65M -822M -3.94M -3.39M -3.19M -2.91M -5.44M -375M -5.46M -37.81M -14.61M -191M -14.78M -14.46M -605M
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!